4D Molecular Therapeutics (FDMT) Non-Current Assets (2019 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Non-Current Assets of $107.5 million for Q1 2026, down 41.29% year-over-year from $183.2 million in Q1 2025, and down 29.98% quarter-over-quarter from $153.6 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Non-Current Assets (2019 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Non-Current Assets for 8 consecutive years, with $107.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 41.29% year-over-year to $107.5 million; the TTM figure through Mar 2026 stood at $543.1 million (up 15.7% YoY), while the FY2025 annual figure was $153.6 million, up 22.42% from the prior year.
- Non-Current Assets retreated to $107.5 million in Q1 2026 per FDMT's latest filing, from $153.6 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $183.2 million in Q1 2025 and bottomed at $33.4 million in Q3 2023.
- Historically, Non-Current Assets has averaged $87.2 million across 5 years, with a median of $81.9 million in 2022.
- On a YoY basis, Non-Current Assets climbed as much as 1358.74% in 2022 and fell as far as 57.48% in 2022.
- 4D Molecular Therapeutics' Non-Current Assets stood at $41.3 million in 2022, then increased by 4.76% to $43.3 million in 2023, then jumped by 189.71% to $125.5 million in 2024, then climbed by 22.42% to $153.6 million in 2025, then slipped by 29.98% to $107.5 million in 2026.
- Business Quant data shows FDMT's Non-Current Assets at $107.5 million in Q1 2026, $153.6 million in Q4 2025, and $111.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | 109.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 109.66 Mn |
| Mar 31, 2026 | 107.54 Mn |
| Dec 31, 2025 | 153.58 Mn |
| Sep 30, 2025 | 111.61 Mn |
| Jun 30, 2025 | 170.35 Mn |
| Mar 31, 2025 | 183.16 Mn |
| Dec 31, 2024 | 125.45 Mn |
| Sep 30, 2024 | 93.27 Mn |
| Jun 30, 2024 | 67.48 Mn |
| Mar 31, 2024 | 94.30 Mn |
| Dec 31, 2023 | 43.30 Mn |
| Sep 30, 2023 | 33.37 Mn |
| Jun 30, 2023 | 34.73 Mn |
| Mar 31, 2023 | 36.98 Mn |
| Dec 31, 2022 | 41.34 Mn |
| Sep 30, 2022 | 47.69 Mn |
| Jun 30, 2022 | 56.41 Mn |
| Mar 31, 2022 | 81.88 Mn |
| Dec 31, 2021 | 97.21 Mn |
| Sep 30, 2021 | 74.89 Mn |